Researchers are exploring treatments that will keep people with cystic fibrosis as healthy as possible until a cure is found. In the first plenary at the NACFC, two CF scientists explain the progress of current research.
Site Search
For those of us without a medication that targets our cystic fibrosis mutation, it's important to remember that our life with CF is a marathon.
With a record 45 clinical trials either ongoing or starting up in 2016, research coordinators and principal investigators throughout the Therapeutics Development Network took time out in San Antonio recently to discuss clinical research and put attendees through boot camp.
The CF Foundation is focused on bringing forward new therapies to help people with CF enjoy the best health and quality of life.
As the mother of a child with CF and volunteer for the CF Foundation, I know first-hand the extraordinary things that Dr. Bob Beall has done for our community, and I am grateful for the legacy of hope that he leaves behind.
Dr. Skach discusses the latest advances in CF research and exciting new approaches to address the underlying cause of the disease.
Earlier this month, we learned that the new CF drug Orkambi was approved by the FDA. This was such an exciting, memorable and emotional day for everyone in the CF community. We heard from many who were thrilled about the potential for this drug to help people with CF and also heard from those who would not benefit from this breakthrough. Following are some reactions from those this impacts the most: people with CF and their loved ones.
Hear from John P. Clancy, M.D., the first plenary speaker at this year's NACFC, about recent advances in personalized medicine, which could allow clinicians to better tailor treatment to the individual with CF.
I've lived my whole life like it has an early expiration date. Recently, a drug was FDA-approved that could change that. I'm grateful, but I'm also scared…
The Foundation hosted a small conference that brought together CF scientists, clinical researchers, and biotechnology and pharmaceutical industry representatives. Learn more and watch a short video of attendees sharing their thoughts about the progress we are making in CF research.